Status:
TERMINATED
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Lead Sponsor:
Summit Therapeutics
Collaborating Sponsors:
Department of Health and Human Services
Conditions:
Clostridioides Difficile Infection
Eligibility:
All Genders
12-17 years
Phase:
PHASE3
Brief Summary
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
Eligibility Criteria
Inclusion
- Is aged 12 to \<18 years.
- Has signs and symptoms of CDI including diarrhea such that in the Investigator's opinion CDI antimicrobial therapy is required, and the subject has tested positive for toxin A and/or B of C. difficile in the stool. Diarrhea is defined as ≥ 3 unformed bowel movements (UBMs) based on types 5, 6, 7 on the Bristol Stool Chart and diarrhea information is within 24 hours prior to randomization.
Exclusion
- Has had more than the equivalent of 48 hours of dosing of antimicrobial treatment active against the current episode of CDI prior to randomization.
- Has received ridinilazole or an investigational vaccine against C. difficile any time in the past, anti-toxic antibodies including bezlotoxumab within the past 6 months, or any other investigational medicinal product for treatment of CDI or fecal microbiota replacement therapy within the past 3 months.
- Has a clinically relevant positive stool test for pathogens other than C. difficile, within 48 hours of randomization.
- Has life-threatening or fulminant CDI with evidence of hypotension, septic shock, peritoneal signs or absence of bowel sounds, toxic megacolon, or ileus.
- Has had major GI surgery (e.g. significant bowel resection or pancreatectomy but not including appendectomy or cholecystectomy) within past 3 months or has the presence of a colostomy or ileostomy or has the likely requirement of an ostomy during the study.
- Is receiving treatment that generally is associated with severe diarrhea, intractable vomiting, severe nausea, or inability to swallow that cannot be managed with antiemetics or antidiarrheals and that limits the ability to take oral medications. Cancer treatment that does not comprise ability to take study medication or cause severe diarrhea is allowed.
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 28 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04802837
Start Date
May 19 2021
End Date
September 28 2022
Last Update
August 21 2023
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles (UCLA) David Geffen School of Medicine
Los Angeles, California, United States, 90095
2
Children's Hospital Orange County
Orange, California, United States, 92868
3
Continental Clinical Research
Miami, Florida, United States, 33144
4
Dynamic Medical Research LLC
Miami, Florida, United States, 33144